DBV Technologies SA patch therapy for peanut allergy Viaskin Peanut missed the primary endpoint in its Phase III PETITES study, sending the company's share price down on NASDAQ by 46% to $25.95 on 23 Oct.
While the top-line results showed a significant response with a favorable tolerability profile, with 35.3% of patients responding to Viaskin...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)